argenx (NASDAQ:ARGX) Given “Overweight” Rating at Piper Sandler

Piper Sandler restated their overweight rating on shares of argenx (NASDAQ:ARGX) in a report issued on Monday, Benzinga reports. Piper Sandler currently has a $522.00 price objective on the stock.

Several other analysts also recently issued reports on the company. Robert W. Baird dropped their price target on argenx from $505.00 to $490.00 and set an outperform rating on the stock in a research note on Friday, March 1st. JMP Securities lowered their target price on argenx from $471.00 to $468.00 and set a market outperform rating on the stock in a research report on Friday, May 10th. Wells Fargo & Company lifted their target price on argenx from $472.00 to $478.00 and gave the company an overweight rating in a research report on Tuesday, February 20th. JPMorgan Chase & Co. lowered their target price on argenx from $560.00 to $500.00 and set an overweight rating on the stock in a research report on Monday, May 13th. Finally, Morgan Stanley lowered their target price on argenx from $515.00 to $510.00 and set an overweight rating on the stock in a research report on Tuesday, May 28th. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $520.68.

argenx Trading Down 2.2 %

Shares of argenx stock opened at $378.30 on Monday. The company has a market capitalization of $22.48 billion, a PE ratio of -66.84 and a beta of 0.65. argenx has a 12 month low of $327.73 and a 12 month high of $550.76. The stock’s fifty day simple moving average is $375.08 and its 200 day simple moving average is $388.61.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.33). argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. The business had revenue of $412.51 million for the quarter, compared to analyst estimates of $404.03 million. During the same period in the previous year, the business posted ($0.52) EPS. Analysts predict that argenx will post -2.75 EPS for the current fiscal year.

Institutional Investors Weigh In On argenx

Several institutional investors have recently made changes to their positions in ARGX. Parkside Financial Bank & Trust bought a new stake in shares of argenx in the third quarter valued at approximately $28,000. GAMMA Investing LLC raised its position in argenx by 420.0% during the first quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after purchasing an additional 63 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in argenx during the fourth quarter valued at approximately $38,000. Mather Group LLC. acquired a new position in argenx during the first quarter valued at approximately $38,000. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in argenx during the fourth quarter valued at approximately $60,000. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.